Literature DB >> 15037514

Effect of acute and chronic lamotrigine on basal and stimulated extracellular 5-hydroxytryptamine and dopamine in the hippocampus of the freely moving rat.

Shagufta Ahmad1, Leslie J Fowler, Peter S Whitton.   

Abstract

1. We have studied the effects of acute and chronic treatment with the anticonvulsant lamotrigine (LTG) on basal and stimulated extracellular 5-hydroxytryptamine (5-HT), dopamine (DA) and their metabolites in the hippocampus of freely moving rats using in vivo microdialysis. 2. Acute LTG (10 and 20 mg kg(-1)) decreased extracellular 5-HT, but had no effect on its metabolite 5-hydroxyindoleacetic acid (5-HIAA). Dialysate DA was also decreased by LTG as were its metabolites dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA). When transmitter release was stimulated by either 50 microm veratridine or 100 mm K(+), marked increases in the release of both transmitters occurred, but LTG was entirely without effect on this. 3. In chronic experiments, rats were dialysed after 2, 4, 7, 14 and 21 days of LTG treatment (5 mg kg(-1), twice daily). During this period a progressively different response to the drug was seen. After 2 days, basal extracellular 5-HT was significantly greater in treated rats than control rats. This effect persisted up to 14 days, but by 21 days 5-HT levels had returned to control values. 5-HIAA levels were unaltered and there was no effect of LTG on veratridine or K(+) stimulated 5-HT release. 4. Similarly, DA concentrations significantly increased after 2-7 days of LTG treatment, but returned and remained at basal values thereafter. During the treatment period LTG had no effect on extracellular DOPAC, but HVA followed a similar pattern to its parent transmitter. As with 5-HT, at no time point did LTG have any effect on stimulated DA release. 5. These neurochemical findings observed in these experiments are considered in relation to the use of LTG in bipolar disorder.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15037514      PMCID: PMC1574927          DOI: 10.1038/sj.bjp.0705737

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  33 in total

1.  Lamotrigine inhibits the in situ activity of tyrosine hydroxylase in striatum of audiogenic seizure-prone and audiogenic seizure-resistant Balb/c mice.

Authors:  J Vriend; N A Alexiuk
Journal:  Life Sci       Date:  1997       Impact factor: 5.037

2.  Plasma and urinary serotonin and 5-HIAA in children treated with lamotrigine for intractable epilepsy.

Authors:  N J Jović; D Mirković; N Majkić-Singh; D D Milovanović
Journal:  Adv Exp Med Biol       Date:  1999       Impact factor: 2.622

3.  Biphasic effects of carbamazepine on the dopaminergic system in rat striatum and hippocampus.

Authors:  M Okada; T Hirano; K Mizuno; T Chiba; Y Kawata; K Kiryu; K Wada; H Tasaki; S Kaneko
Journal:  Epilepsy Res       Date:  1997-09       Impact factor: 3.045

4.  Studies on the mechanism of action of the novel anticonvulsant lamotrigine (Lamictal) using primary neurological cultures from rat cortex.

Authors:  G Lees; M J Leach
Journal:  Brain Res       Date:  1993-05-28       Impact factor: 3.252

5.  N-methyl-d-aspartate receptors modulate extracellular dopamine concentration and metabolism in rat hippocampus and striatum in vivo.

Authors:  P S Whitton; S Maione; C S Biggs; L J Fowler
Journal:  Brain Res       Date:  1994-01-28       Impact factor: 3.252

6.  Regional effects of sodium valproate on extracellular concentrations of 5-hydroxytryptamine, dopamine, and their metabolites in the rat brain: an in vivo microdialysis study.

Authors:  C S Biggs; B R Pearce; L J Fowler; P S Whitton
Journal:  J Neurochem       Date:  1992-11       Impact factor: 5.372

7.  Lamotrigine inhibits monoamine uptake in vitro and modulates 5-hydroxytryptamine uptake in rats.

Authors:  E Southam; D Kirkby; G A Higgins; R M Hagan
Journal:  Eur J Pharmacol       Date:  1998-09-25       Impact factor: 4.432

Review 8.  Lamotrigine: a review of its use in bipolar disorder.

Authors:  David R Goldsmith; Antona J Wagstaff; Tim Ibbotson; Caroline M Perry
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 9.  Serotonin and psychiatric disorders.

Authors:  J J López-Ibor
Journal:  Int Clin Psychopharmacol       Date:  1992-10       Impact factor: 1.659

Review 10.  Long-term treatment of bipolar disorder with lamotrigine.

Authors:  Joseph R Calabrese; Melvin D Shelton; Daniel J Rapport; Susan E Kimmel; Omar Elhaj
Journal:  J Clin Psychiatry       Date:  2002       Impact factor: 4.384

View more
  14 in total

1.  Lamotrigine inhibits basal and Na+-stimulated, but not Ca2+-stimulated, release of corticotropin-releasing hormone from the rat hypothalamus.

Authors:  Giuseppe Tringali; Jean Michel Aubry; Pierluigi Navarra; Giacomo Pozzoli
Journal:  Psychopharmacology (Berl)       Date:  2006-09-01       Impact factor: 4.530

2.  Effect of lamotrigine and carbamazepine on corticotropin-releasing factor-associated serotonergic transmission in rat dorsal raphe nucleus.

Authors:  Shunske Tanahashi; Satoshi Yamamura; Masanori Nakagawa; Eishi Motomura; Motohiro Okada
Journal:  Psychopharmacology (Berl)       Date:  2011-09-27       Impact factor: 4.530

3.  Evidence for the activity of lamotrigine at 5-HT(1A) receptors in the mouse forced swimming test.

Authors:  Michel Bourin; Fabienne Masse; Martine Hascoët
Journal:  J Psychiatry Neurosci       Date:  2005-07       Impact factor: 6.186

Review 4.  The potential role of lamotrigine in schizophrenia.

Authors:  Charles H Large; Elizabeth L Webster; Donald C Goff
Journal:  Psychopharmacology (Berl)       Date:  2005-10-12       Impact factor: 4.530

5.  Effects of combined lamotrigine and valproate on basal and stimulated extracellular amino acids and monoamines in the hippocampus of freely moving rats.

Authors:  Shagufta Ahmad; Leslie J Fowler; Peter S Whitton
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-01-20       Impact factor: 3.000

Review 6.  Mood-stabilizers target the brain arachidonic acid cascade.

Authors:  Jagadeesh S Rao; Stanley I Rapoport
Journal:  Curr Mol Pharmacol       Date:  2009-06       Impact factor: 3.339

7.  Comorbidity between temporal lobe epilepsy and depression: a [18F]MPPF PET study.

Authors:  A Lothe; A Didelot; A Hammers; N Costes; M Saoud; F Gilliam; P Ryvlin
Journal:  Brain       Date:  2008-09-02       Impact factor: 13.501

8.  FXR1P is a GSK3β substrate regulating mood and emotion processing.

Authors:  Thomas Del'Guidice; Camille Latapy; Antonio Rampino; Jivan Khlghatyan; Morgane Lemasson; Barbara Gelao; Tiziana Quarto; Giuseppe Rizzo; Annie Barbeau; Claude Lamarre; Alessandro Bertolino; Giuseppe Blasi; Jean-Martin Beaulieu
Journal:  Proc Natl Acad Sci U S A       Date:  2015-08-03       Impact factor: 11.205

9.  Effect of lamotrigine on cerebral blood flow in patients with idiopathic generalised epilepsy.

Authors:  Eun Yeon Joo; Seung Bong Hong; Woo Suk Tae; Sun Jung Han; Dae Won Seo; Kyung-Han Lee; Mann Hyung Lee
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-03-10       Impact factor: 9.236

10.  Chronic administration of lamotrigine downregulates COX-2 mRNA and protein in rat frontal cortex.

Authors:  Ho-Joo Lee; Renee N Ertley; Stanley I Rapoport; Richard P Bazinet; Jagadeesh S Rao
Journal:  Neurochem Res       Date:  2007-12-14       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.